Novel agents that downregulate EGFR, HER2, and HER3 in parallel
about
Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas.CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment.
P2860
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
@ast
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
@en
type
label
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
@ast
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
@en
prefLabel
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
@ast
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
@en
P2093
P2860
P50
P356
P1433
P1476
Novel agents that downregulate EGFR, HER2, and HER3 in parallel
@en
P2093
Bradley John Davis
Brian Keith Law
Mary Elizabeth Law
Mary Reinhard
Stephan Christopher Jahn
P2860
P304
10445-10459
P356
10.18632/ONCOTARGET.3398
P407
P577
2015-04-01T00:00:00Z